Aurinia Pharmaceuticals (AUPH) Gets a Buy Rating from H.C. Wainwright

In a report released yesterday, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals (AUPHResearch Report), with a price target of $25.00. The company’s shares closed last Monday at $4.96.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.5% and a 34.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Madrigal Pharmaceuticals Inc, and Arcturus Therapeutics Ltd.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $16.67 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.85 and a one-year low of $3.52. Currently, Aurinia Pharmaceuticals has an average volume of 788.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.